Diabetic gastroparesis and refractory GERD diet tips
Metozolv ODT treats symptoms of diabetic gastroparesis and refractory GERD.1 However, paying special attention to what you eat and drink may help make an impact on your symptoms. Before making changes to your diet, it is important that you discuss them with your healthcare professional or a registered dietician.
Changing your dietary habits alone is not a substitute for treatment. But when monitored by a healthcare professional, dietary modifications along with medication can aid in treatment.
Diabetic gastroparesis diet tips
Reduce food volume
Eating smaller, more frequent meals each day may be an appropriate diabetic gastroparesis diet for some people. Eating between 6 and 8 smaller meals each day may prevent the stomach from filling up too quickly, while allowing the body to get the nourishment it needs.
Consume liquid calories
Drinking liquid and pureed or blended foods may be more tolerable than solid foods for some people. Liquids will empty from the stomach faster than solid foods, helping alleviate symptoms. Reserving solid foods for the morning and liquids for later in the day may also help reduce symptoms.
Limit fiber and fats
Foods heavy in fiber and fat are harder for the body to digest and may slow the speed at which the stomach empties.
Refractory GERD diet tips
Maintain a healthy weight
If you are overweight or obese, losing weight may help reduce symptoms. Even a few pounds can make a difference.
Watch what you eat and drink
A good refractory GERD diet may be more about what you don’t eat than what you do eat. Avoiding alcohol, carbonated drinks, fatty foods, spicy foods, chocolate, citrus fruits and juices, and mint may help prevent some symptoms. For the most part, however, there is not enough evidence to support that avoiding these foods and drinks alone will prove successful in refractory GERD prevention.
The best way to see what does and does not work for you is to keep track of what you eat and when you eat it, so that you may discover a connection with an increase in symptoms. You can download our food diary to help you track your diet.
Tools to help manage your diet and weight
Managing your diet and weight takes dedication, so we’ve provided several tools to help. But remember that you should talk to your healthcare professional or a registered dietician before making changes to your diet.
Understanding food labels
BMI calculator
Food diary
Reference: 1. METOZOLV ODT [package insert]. Morrisville, NC: Salix Pharmaceuticals, Inc; 2009.
IMPORTANT SAFETY INFORMATION
Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive
dyskinesia increases with the duration of treatment and the total cumulative dose.
Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive
dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.
Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh
the risk of developing tardive dyskinesia.
METOZOLV™ ODT (metoclopramide HCl) is indicated as short-term therapy for adults with symptomatic, documented gastroesophageal reflux disease (GERD)
who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric
stasis) in adults. Therapy should not exceed 12 weeks in duration. METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage,
or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal
reactions. METOZOLV ODT should be used with caution in patients showing acute dystonic reactions, drug-induced Parkinsonism, or other extrapyramidal symptoms;
neuroleptic malignant syndrome; with a prior history of depression; hypertension; congestive heart failure and ventricular arrhythmia. Patients may experience
withdrawal symptoms after stopping the use of METOZOLV ODT.
In clinical studies, the most frequently reported adverse events (≥2% occurrence) were headache, nausea, fatigue, somnolence, and vomiting.
Please see accompanying full Prescribing Information
for Metozolv ODT, including BOXED WARNING.